391 related articles for article (PubMed ID: 27451093)
1. The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Mónica FZ; Bian K; Murad F
Adv Pharmacol; 2016; 77():1-27. PubMed ID: 27451093
[TBL] [Abstract][Full Text] [Related]
2. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility.
Ghalayini IF
Int J Impot Res; 2004 Dec; 16(6):459-69. PubMed ID: 15229623
[TBL] [Abstract][Full Text] [Related]
4. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
Breitenstein S; Roessig L; Sandner P; Lewis KS
Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
[TBL] [Abstract][Full Text] [Related]
5. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
Krishnan SM; Kraehling JR; Eitner F; Bénardeau A; Sandner P
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890734
[TBL] [Abstract][Full Text] [Related]
6. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
Sandner P; Stasch JP
Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058
[TBL] [Abstract][Full Text] [Related]
7. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases.
Dupont LL; Glynos C; Bracke KR; Brouckaert P; Brusselle GG
Pulm Pharmacol Ther; 2014 Oct; 29(1):1-6. PubMed ID: 25043200
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
[TBL] [Abstract][Full Text] [Related]
10. Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice.
Decaluwé K; Pauwels B; Boydens C; Thoonen R; Buys ES; Brouckaert P; Van de Voorde J
J Sex Med; 2017 Feb; 14(2):196-204. PubMed ID: 28161078
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview.
Evora PR; Evora PM; Celotto AC; Rodrigues AJ; Joviliano EE
Curr Drug Targets; 2012 Aug; 13(9):1207-14. PubMed ID: 22716077
[TBL] [Abstract][Full Text] [Related]
12. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
13. The importance of the nitric oxide-cGMP pathway in age-related cardiovascular disease: Focus on phosphodiesterase-1 and soluble guanylate cyclase.
Golshiri K; Ataei Ataabadi E; Portilla Fernandez EC; Jan Danser AH; Roks AJM
Basic Clin Pharmacol Toxicol; 2020 Aug; 127(2):67-80. PubMed ID: 31495057
[TBL] [Abstract][Full Text] [Related]
14. Conventional and Unconventional Mechanisms for Soluble Guanylyl Cyclase Signaling.
Gao Y
J Cardiovasc Pharmacol; 2016 May; 67(5):367-72. PubMed ID: 26452163
[TBL] [Abstract][Full Text] [Related]
15. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
Sandner P; Berger P; Zenzmaier C
Gerontology; 2017; 63(3):216-227. PubMed ID: 27784018
[TBL] [Abstract][Full Text] [Related]
16. What is next in nitric oxide research? From cardiovascular system to cancer biology.
Bian K; Murad F
Nitric Oxide; 2014 Dec; 43():3-7. PubMed ID: 25153032
[TBL] [Abstract][Full Text] [Related]
17. cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.
Hoffmann LS; Chen HH
Naunyn Schmiedebergs Arch Pharmacol; 2014 Aug; 387(8):707-18. PubMed ID: 24927824
[TBL] [Abstract][Full Text] [Related]
18. Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease.
Cortese-Krott MM; Mergia E; Kramer CM; Lückstädt W; Yang J; Wolff G; Panknin C; Bracht T; Sitek B; Pernow J; Stasch JP; Feelisch M; Koesling D; Kelm M
Redox Biol; 2018 Apr; 14():328-337. PubMed ID: 29024896
[TBL] [Abstract][Full Text] [Related]
19. A primer for measuring cGMP signaling and cGMP-mediated vascular relaxation.
Straub AC; Beuve A
Nitric Oxide; 2021 Dec; 117():40-45. PubMed ID: 34601102
[TBL] [Abstract][Full Text] [Related]
20. Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.
Kopra K; Sharina I; Martin E; Härmä H
Sci Rep; 2020 Oct; 10(1):17469. PubMed ID: 33060787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]